Literature DB >> 23929710

Systematic test of neurotoxin dose and volume on muscle function in a rat model.

Jonah B Hulst1, Viviane B Minamoto, Michael B Lim, Shannon N Bremner, Samuel R Ward, Richard L Lieber.   

Abstract

INTRODUCTION: Onabotulinum toxin serotype A (BT-A) is used for a variety of motor and sensory disorders related to abnormal muscle activity.
METHODS: We developed a high-resolution rodent model to allow precise determination of the effect of BT-A dose (measured in units) and injectate volume (measured in μl) on the efficacy of the injection and systemic side effects. Dorsiflexion is the best indicator of injected and contralateral muscle function.
RESULTS: One month after injection, dorsiflexion torque of BT-A-injected limbs was decreased significantly in all experimental groups compared with saline controls (P < 0.05). Torque was also compared among the BT-A groups, which demonstrated a significant effect of dose (P < 0.001), but no effect of volume (P > 0.2) and no dose × volume interaction (P > 0.3). Similar results were observed for other parameters measured.
CONCLUSIONS: These data demonstrate that injection dose and not volume or concentration is the primary determinant of neurotoxin efficacy in a rodent model.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Onabotulinum toxin; cerebral palsy; fibrosis; myopathy; spasticity

Mesh:

Substances:

Year:  2014        PMID: 23929710      PMCID: PMC4565491          DOI: 10.1002/mus.23983

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  34 in total

1.  Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.

Authors:  Markus Naumann; Alastair Carruthers; Jean Carruthers; Sheena K Aurora; Ross Zafonte; Susan Abu-Shakra; Terry Boodhoo; Mary Ann Miller-Messana; George Demos; Lynn James; Frederick Beddingfield; Amanda VanDenburgh; Mary Ann Chapman; Mitchell F Brin
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

Review 2.  Pharmacotherapy of spasticity in children with cerebral palsy.

Authors:  Alberto Verrotti; Rita Greco; Alberto Spalice; Francesco Chiarelli; Paola Iannetti
Journal:  Pediatr Neurol       Date:  2006-01       Impact factor: 3.372

3.  SV2 is the protein receptor for botulinum neurotoxin A.

Authors:  Min Dong; Felix Yeh; William H Tepp; Camin Dean; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Science       Date:  2006-03-16       Impact factor: 47.728

4.  Stress-dependent and -independent expression of the myogenic regulatory factors and the MARP genes after eccentric contractions in rats.

Authors:  Eric R Hentzen; Michele Lahey; David Peters; Liby Mathew; Ilona A Barash; Jan Fridén; Richard L Lieber
Journal:  J Physiol       Date:  2005-10-20       Impact factor: 5.182

5.  Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia.

Authors:  Nathaniel H Mayer; John Whyte; Gunilla Wannstedt; Colin A Ellis
Journal:  Arch Phys Med Rehabil       Date:  2008-05       Impact factor: 3.966

6.  Scaling of muscle architecture and fiber types in the rat hindlimb.

Authors:  Carolyn M Eng; Laura H Smallwood; Maria Pia Rainiero; Michele Lahey; Samuel R Ward; Richard L Lieber
Journal:  J Exp Biol       Date:  2008-07       Impact factor: 3.312

7.  Different recovery of the train-of-four ratio from rocuronium-induced neuromuscular blockade in the diaphragm and the tibialis anterior muscle in rat.

Authors:  Takeshi Osawa
Journal:  J Anesth       Date:  2008-08-07       Impact factor: 2.078

8.  Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation.

Authors:  Viviane B Minamoto; Jonah B Hulst; Michael Lim; William J Peace; Shannon N Bremner; Samuel R Ward; Richard L Lieber
Journal:  Dev Med Child Neurol       Date:  2007-12       Impact factor: 5.449

9.  Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study.

Authors:  Jean-Michel Gracies; Mara Lugassy; Donald J Weisz; Michele Vecchio; Steve Flanagan; David M Simpson
Journal:  Arch Phys Med Rehabil       Date:  2009-01       Impact factor: 3.966

10.  Effects of Botox and Neuronox on muscle force generation in mice.

Authors:  Austin V Stone; Jianjun Ma; Patrick W Whitlock; L Andrew Koman; Thomas L Smith; Beth P Smith; Michael F Callahan
Journal:  J Orthop Res       Date:  2007-12       Impact factor: 3.494

View more
  5 in total

1.  Chronic Degeneration Leads to Poor Healing of Repaired Massive Rotator Cuff Tears in Rats.

Authors:  Megan L Killian; Leonardo M Cavinatto; Samuel R Ward; Necat Havlioglu; Stavros Thomopoulos; Leesa M Galatz
Journal:  Am J Sports Med       Date:  2015-08-21       Impact factor: 6.202

2.  Recovery of rat muscle size but not function more than 1 year after a single botulinum toxin injection.

Authors:  Samuel R Ward; Viviane B Minamoto; Kentaro P Suzuki; Jonah B Hulst; Shannon N Bremner; Richard L Lieber
Journal:  Muscle Nerve       Date:  2017-06-15       Impact factor: 3.217

3.  Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections.

Authors:  Viviane B Minamoto; Kentaro P Suzuki; Shannon N Bremner; Richard L Lieber; Samuel R Ward
Journal:  Muscle Nerve       Date:  2015-06-30       Impact factor: 3.217

Review 4.  Over 25 Years of Pediatric Botulinum Toxin Treatments: What Have We Learned from Injection Techniques, Doses, Dilutions, and Recovery of Repeated Injections?

Authors:  Heli Sätilä
Journal:  Toxins (Basel)       Date:  2020-07-06       Impact factor: 4.546

5.  Botulinum toxin A-induced muscle paralysis stimulates Hdac4 and differential miRNA expression.

Authors:  Leah E Worton; Edith M Gardiner; Ronald Y Kwon; Leah M Downey; Brandon J Ausk; Steven D Bain; Ted S Gross
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.